ACE-031

ACE-031 is a recombinant fusion protein pairing the extracellular ligand-binding domain of the human activin receptor type IIB (ActRIIB) with the Fc region of human immunoglobulin G1. Investigators developed it as a structurally defined research material for studies of the myostatin / activin signaling axis, where a soluble decoy receptor sequesters TGF-β-superfamily ligands before they engage the membrane-bound receptor. The peer-reviewed literature catalogs ActRIIB-Fc constructs in myostatin (GDF-8) signaling research, activin-pathway investigations, and structure-activity work on the ActRIIB ligand-binding interface. Supplied for laboratory characterization, in-vitro ligand-binding work, and in-cell signaling studies only. For research use only; not for human consumption, medical use, or veterinary application. Researchers should consult primary literature for context-specific experimental conditions and validated assay controls.

ACE-031 is a homodimeric Fc-fusion glycoprotein: two ActRIIB extracellular-domain arms joined through the disulfide-linked IgG1 Fc hinge, a format documented across the published literature for extending the plasma residence of a soluble receptor ectodomain. The ActRIIB domain retains the ligand-recognition surface that binds myostatin (GDF-8), activin A, and related TGF-β-superfamily ligands, functioning as a ligand trap that reduces signaling through the native ActRIIB / Smad2/3 cascade. Because it is a decoy receptor rather than a receptor agonist, the documented interaction profile is defined by ligand-capture affinity rather than downstream receptor activation. Pharmacokinetic descriptors documented in published animal-model investigations reflect the extended systemic residence characteristic of Fc-fusion proteins. All activity descriptors here are framed as documented in published research rather than as effects of the supplied product. Identity is established by SDS-PAGE, size-exclusion chromatography, and mass spectrometry on each Certificate of Analysis.

Experimental domains documented in the published literature include myostatin (GDF-8) ligand-capture assays, activin-A binding studies, ActRIIB / Smad2/3 signaling investigations in cell-culture models, comparative structure-activity work on soluble-receptor decoy constructs, and animal-model research into the muscle-and-bone consequences of TGF-β-superfamily ligand sequestration. Investigators use ActRIIB-Fc research materials to parse the contribution of individual ligands to ActRIIB signaling and to screen the ligand-binding interface. Use in laboratory research extends to mechanism-elucidation paradigms where the fusion protein serves as a defined ligand trap for the myostatin / activin family. The reference material is supplied for these and equivalent in-vitro and animal-model experimental contexts only, with no associated guidance for human, clinical, or veterinary use.

Each lot is characterized by reverse-phase and size-exclusion HPLC for chromatographic purity and aggregation state, by SDS-PAGE for apparent molecular weight under reducing and non-reducing conditions, and by mass spectrometry for subunit-mass confirmation. Purity is reported as an HPLC-area percentage on the Certificate of Analysis distributed with every lot. Disulfide-linked dimer integrity and glycosylation heterogeneity are reported categorically when these parameters are part of the lot release specification, as expected for an Fc-fusion glycoprotein. Endotoxin content is reported when included in the release specification. The COA records the lot identifier, manufacturing date, and analytical method versions used, providing a traceable provenance chain from expression through release. Researchers requiring batch-level analytical detail should reference the COA distributed with the supplied material.

For laboratory storage, the lyophilized fusion protein should be held at −20°C in its sealed, light-protected container until ready for analytical use. Allow vials to equilibrate to ambient temperature before opening to avoid moisture condensation on the lyophile. Reconstitution for in-vitro experimental use is typically performed in a sterile buffer compatible with the downstream assay; once reconstituted, store the working solution at 2–8°C and characterize stability in the relevant buffer prior to extended storage. As with other Fc-fusion glycoproteins, avoid repeated freeze-thaw cycles of reconstituted material — single-use aliquots are preferred where protein integrity is assay-critical — and avoid vigorous agitation that can drive aggregation. These handling parameters reflect general best-practice for recombinant fusion-protein reference materials and do not constitute preparation guidance for human or veterinary use.